South Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's obesity treatment Eppe on October 8, 2026, making it the country's first domestically developed GLP-1-based drug for chronic weight management and Hanmi's 45th approved novel drug overall.
What Eppe Is
Eppe is an injectable GLP-1 receptor agonist approved for chronic weight management in adults with obesity, or in overweight adults without diabetes, to be used alongside a reduced-calorie diet and exercise. It is available in five dose strengths — 2, 4, 6, 8, and 10 milligrams — intended to allow gradual dose escalation, a pattern similar to how other approved GLP-1 drugs are introduced. Hanmi plans to manufacture the drug at its Pyeongtaek biopharmaceutical plant and launch it in South Korea by the end of 2026.
A Long Road to Approval
Eppe's regulatory path illustrates how drug development doesn't always move in a straight line. Hanmi first licensed the molecule to Sanofi in 2015 as a candidate diabetes treatment. Sanofi returned the rights in 2020, after which Hanmi redeveloped the compound specifically as an obesity treatment rather than a diabetes drug — a pivot that took roughly six more years to reach approval.
How It Fits Into the Market
Eppe enters a South Korean obesity-drug market currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Mounjaro-based products. As a later entrant from a domestic manufacturer, Eppe is widely expected to be priced more competitively than either import. The approval also adds a third competitor to a market where Novo Nordisk and Eli Lilly have separately filed their respective oral obesity pills — Wegovy Pill and Foundayo — for approval with the same South Korean regulator, as PeptideAAA covered previously. Reporting on Eppe's approval did not include head-to-head efficacy or safety comparisons against Wegovy or Mounjaro, so it isn't yet possible to say how the three options stack up clinically; that typically becomes clearer only after a drug has been on the market and generated real-world and comparative trial data.
What's Not Yet Known
Public reporting on this approval did not include detailed trial results, such as average weight loss, trial duration, or side-effect rates — information that is standard for approvals in the United States and European Union but is not always disclosed the same way by every regulator at the time of a domestic approval announcement. Readers should treat efficacy and safety claims about Eppe as unverified until Hanmi or regulators publish underlying trial data.
Why It Matters Beyond Korea
Domestic obesity-drug approvals outside the U.S. and Europe are becoming more common as more countries develop their own incretin-based candidates rather than relying solely on Novo Nordisk and Eli Lilly. For a company like Hanmi, a home-market approval is also a proof point it can use when licensing or partnering the drug for other markets. Whether Eppe is eventually filed with the FDA, and what evidence would support that filing, remains to be seen.
Regulatory Status
Eppe's approval is specific to South Korea. It is not an FDA-approved drug in the United States, and nothing about this approval changes the regulatory status of any GLP-1 medication sold in the U.S. As with any prescription weight-management drug, use should be guided by a licensed physician who can weigh it against alternatives already approved in a given country.